Completed PHASE1 INTERVENTIONAL 2-arm NCT01023282

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure

Sponsor: NeuroSearch A/S

Conditions Parkinson's Disease Tolerability

Interventions ACR325 Placebo

Updated 5 times since 2017 Last updated: Nov 1, 2011 Started: Nov 30, 2009 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Parkinson's Disease and Tolerability and is currently completed. NeuroSearch A/S leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeuroSearch A/S

Data source: NeuroSearch A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kassel, Germany
• Marburg, Germany